Crossmark

Mutational processes shape the landscape of TP53 mutations in human cancer

Crossref DOI link: https://doi.org/10.1038/s41588-018-0204-y

Published Online: 2018-09-17

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Giacomelli, Andrew O. http://orcid.org/0000-0003-2109-0458
Yang, Xiaoping

Lintner, Robert E.

McFarland, James M.

Duby, Marc

Kim, Jaegil

Howard, Thomas P. http://orcid.org/0000-0002-3438-2831
Takeda, David Y.

Ly, Seav Huong

Kim, Eejung

Gannon, Hugh S.

Hurhula, Brian

Sharpe, Ted

Goodale, Amy

Fritchman, Briana

Steelman, Scott

Vazquez, Francisca http://orcid.org/0000-0002-2857-4685
Tsherniak, Aviad http://orcid.org/0000-0002-3797-1877
Aguirre, Andrew J.

Doench, John G. http://orcid.org/0000-0002-3707-9889
Piccioni, Federica http://orcid.org/0000-0003-1210-3210
Roberts, Charles W. M.

Meyerson, Matthew http://orcid.org/0000-0002-9133-8108
Getz, Gad http://orcid.org/0000-0002-0936-0753
Johannessen, Cory M.

Root, David E.

Hahn, William C. http://orcid.org/0000-0003-2840-9791
License Information

Text and Data Mining valid from 2018-09-17
More Information

Article History

Received: 22 November 2017

Accepted: 26 July 2018

First Online: 17 September 2018

Competing interests

: M.M. is a consultant for OrigiMed and receives research support from Bayer. W.C.H. is a consultant for KSQ Therapeutics.